Ruxolitinib (Opzelura)

What is ruxolitinib?

Ruxolitinib (Opzelura) is a topical JAK inhibitor used in dermatology to help reduce inflammation in the skin. It is primarily used for mild-to-moderate atopic dermatitis and nonsegmental vitiligo. Unlike topical steroids, it does not cause skin thinning and is often considered for sensitive areas such as the face or skin folds when appropriate.

Ruxolitinib may also be discussed for certain other inflammatory skin conditions in select situations, but its best-established dermatologic uses are eczema and vitiligo.

How does ruxolitinib work?

Ruxolitinib works by blocking JAK signaling in the skin. These pathways help drive inflammation in conditions such as eczema and vitiligo. By reducing this signaling locally in the skin, ruxolitinib can help calm inflammation, improve itch, and in vitiligo help support repigmentation over time.

What are possible side effects of ruxolitinib?

Ruxolitinib cream is generally well tolerated. Possible side effects can include:

• Mild irritation, burning, or redness where the cream is applied

• Acne or small bumps in treated areas

• Itching

• Cold symptoms or headache in some patients

This medication carries a boxed warning related to the broader JAK inhibitor drug class. In practice, topical use on limited areas is very different from taking an oral JAK inhibitor, but your dermatologist will still review whether it is a good fit for your situation.

How is ruxolitinib used?

Ruxolitinib is used as a cream and is typically applied in a thin layer to affected areas as directed by your dermatologist. It is usually used on limited areas of involved skin rather than very large body surface areas. Avoid getting the medication in the eyes, mouth, or on open skin unless specifically directed otherwise.

For eczema, the goal is to reduce inflammation and itching. For vitiligo, improvement is usually gradual and often takes time and consistency.